31 maart 2019: zie ook dit artikel: 


30 augustus 2009: Bron: Pubmed

Rituximab - Mabthera gegeven naast chemotherapie blijkt significant effectief voor mensen met CLL - Chronische Lymfatische Leukemie ouder dan 70 jaar. Dit blijkt uit een gerandomiseerde fase II studie bij 72 voorheen onbehandelde CLL patienten.

1: J Clin Oncol. 2009 Aug 24. [Epub ahead of print]Click here to read Links

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone a New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.
Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, Diaz MG, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E.
Department of Hematology, Hospital Clínic, Institut de Investigacions Biomèdiques "August Pi i Sunyer"; Department of Hematopathology, Hospital Clinic; Hospital "Duran y Reynals," L'Hospitalet; Hospital del Mar; Hospital de Sant Pau, Barcelona; Departments of Hematology, Hospital Clínic; Hospital General Universitario; Hospital Dr Peset; Hospital "Arnau de Vilanova"; Hospital "La Fe," Valencia; Hospital "Germans Trias y Pujol," Badalona; Hospital Clínico Universitario, Salamanca; Hospital Universitario Puerta de Hierro, Madrid; Hospital Joan XXIII, Tarragona; Hospital "Josep Trueta," Girona; and Hospital Mutua de Terrassa, Terrassa, Spain.
PURPOSE: The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of chronic lymphocytic leukemia (CLL). Based on excellent results with the chemotherapy-only regimen fludarabine, cyclophosphamide, and mitoxantrone (FCM), we built a new chemoimmunotherapy combination-rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance.
PATIENTS AND METHODS: Seventy-two untreated CLL patients age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), fludarabine 25 mg/m(2) IV on days 1 to 3, cyclophosphamide 200 mg/m(2) on days 1 to 3, and mitoxantrone 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. Patients achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years.
RESULTS: The overall response, minimal residual disease (MRD) -negative complete response (CR), MRD-positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe neutropenia developed in 13% of patients. Major and minor infections were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum beta2-microglobulin levels correlated with a lower CR rate.
CONCLUSION: R-FCM is highly effective in previously untreated CLL, with an 82% CR rate and a high proportion of MRD-negative CRs (46%). Treatment toxicity is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum beta2-microglobulin levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.

Plaats een reactie ...

Reageer op "Rituximab - Mabthera gegeven naast chemotherapie blijkt significant effectief voor mensen met CLL - Chronische Lymfatische Leukemie ouder dan 70 jaar."

Gerelateerde artikelen

Gerelateerde artikelen

Rituximab - Mabthera - Rituxan >> Rituximab in combinatie met >> Rituximab - Mabthera - Rituxan >> Rituximab - Mabthera toegevoegd >> Rituximab - Mabthera gegeven >> Mabthera - Rituximab - Rituxan >>